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ABSTRACT 
 
IN VIVO BIODISTRIBUTION OF 99mTc-MDP FOR EARLY OSTEOPOROSIS 
MONITORING IN OVARIECTOMIZED BALB/C MICE. Technetium-99m Methylene 
Diphosphonate (99mTc-MDP) has been utilized in a variety of clinical situations to identify bone 
areas due to the strong affinity of hydroxyapatite crystals in the mineral phase of the bone with 
the diphosphonate compounds. Osteoporosis is a disease characterized by decreased bone 
mass and increased fracture risk and represents a significant population health issue. It has been 
observed that 99mTc-MDP can be used for bone scintigraphy especially in case of bone cancer, 
but biodistribution study of 99mTc-MDP on ovariectomized mice for early monitoring of 
osteoporosis model remains unclear. Therefore, we aimed to investigate the biodistribution of 
99mTc-MDP both in normal and ovariectomized mice. The experiment was performed on BALB/c 
mice weighing approximately 30 g. Mice were divided into a normal and ovariectomized group. 
After the first, second and third hours, mice were euthanized using the accepted protocol and the 
tissue of interest was collected. All tissue and blood were weighed using an analytical scale and 
counted for radioactivity using Automatic Gamma Counter with NaI(Tl) detector. Administration of 
99mTc-MDP showed in normal mice compared with an animal model of osteoporosis, there are 
significant differences at 1 hour post-injection from (20.32±1.38) %ID/g decreased to 
(7.42±2.61) %ID/g, 2 hours from (13.75±0.01) %ID/g to (5.25±0.25) %ID/g and 3 hours from 
(12.18±1.44)%ID/g to (4.86±1.34) %ID/g uptake in the bones with (p<0.05). This study can be a 
consideration for the clinical application of 99mTc-MDP for early detection of osteoporosis 
conditions by looking at bone uptake and become a concern in the application for bone 
scintigraphy if the patient is indicated osteoporosis because it will affect visualization of the organ.  
 
Keywords : Radiopharmaceutical, 99mTc-MDP, Osteoporosis, Ovariectomized, Biodistribution. 
 
ABSTRAK  
 
BIODISTRIBUSI IN VIVO 99mTc-MDP PADA MENCIT BALB/C YANG DIOVARIEKTOMI 
UNTUK DETEKSI DINI OSTEOPOROSIS. Technetium-99m Methylene Diphosphonate (99mTc-
MDP) telah digunakan dalam berbagai aplikasi klinis untuk mengidentifikasi area tulang karena 
afinitas senyawa difosfonat yang kuat pada kristal hidroksiapatit. Osteoporosis adalah penyakit 
yang ditandai dengan penurunan massa tulang dan peningkatan risiko patah tulang dan 
merupakan masalah kesehatan yang mengancam populasi secara signifikan. Penelitian 
sebelumnya telah diamati bahwa 99mTc-MDP dapat digunakan untuk skintigrafi tulang terutama 
dalam kasus kanker tulang, tetapi studi biodistribusi 99mTc-MDP pada mencit yang diovariektomi 
untuk pemantauan dini osteoporosis masih belum dilakukan. Oleh karena itu, studi ini bertujuan 
untuk menyelidiki biodistribusi 99mTc-MDP pada mencit normal dan model ovariektomi. 
Percobaan dilakukan pada mencit BALB/c dengan berat sekitar 30 g. Mencit dibagi menjadi 
kelompok normal dan kelompok yang diovariektomi. Kemudian setelah 1, 2, dan 3 jam di-
eutanasia menggunakan protokol yang sudah disetujui dan jaringan yang dibutuhkan 
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dikumpulkan. Semua jaringan dan darah ditimbang menggunakan timbangan analitik dan 
radioaktivitasnya dihitung menggunakan Automatic Gamma Counter dengan detektor NaI(Tl). 
Pemberian 99mTc-MDP menunjukkan pada hewan normal dibandingkan dengan model 
osteoporosis, terdapat perbedaan signifikan pada 1 jam pasca penyuntikan dari (20,32 ± 
1,38) %ID/g menurun menjadi (7,42 ± 2,61) %ID/g, 2 jam dari (13,75 ± 0,01) %ID/g menurun 
hingga (5,25 ± 0,25) %ID/g dan 3 jam dari (12,18 ± 1,44) %ID/g menurun menjadi (4,86 ± 
1,34) %ID/g serapan dalam tulang dengan (p<0,05). Penelitian ini dapat menjadi pertimbangan 
untuk aplikasi klinis 99mTc-MDP untuk deteksi dini kondisi osteoporosis dengan mengamati 
akumulasi pada tulang.  Aplikasi skintigrafi tulang dengan 99mTc-MDP juga harus diperhatikan jika 
pasien diindikasikan osteoporosis karena akan mempengaruhi visualisasi pada organ. 
 
Kata Kunci : Radiofarmasi, 99mTc-MDP, Osteoporosis, Ovariektomi, Biodistribusi  
 
 
 
1. INTRODUCTION 
Osteoporosis is a disease 
characterized by decreased bone mass and 
increased fracture risk. It becomes a 
significant population health issue because of 
its negative effects on mortality, quality of life, 
and other health outcomes (1). A study of  the 
prevalence of osteoporosis cases in the US 
in 2013-2014 for adults above 50 years 
revealed 6% cases at the femur neck, 8% at 
the lumbar spine, and 11% at other bone 
locations (2). The prevalence of cases in 
China also shows an increase in the last 12 
years in which cases of osteoporosis affect 1 
in 3 people 50 years or older (3).  
Diagnosis of osteoporosis is based on 
Bone Mineral Density (BMD) and Dual X-Ray 
Absorptiometry (DXA) and is assisted with a 
minimal number threshold (4). The use of 
BMD and DXA is widely accepted for 
screening and fracture risk assessment. 
However, this method has poor accuracy due 
to several circumstances, such as vertebral 
disease, fracture, bone calcification and 
obesity  (5)(6). 
 
In studies related to the condition of 
osteoporosis, the main choice is to use 
rodents as animal models with an 
ovariectomy procedure(7). Hormonal 
changes especially estrogen, on the 
ovariectomized rodent model are permanent 
compared to other estrogen deficiency 
models. Osteoporosis animal models with 
ovariectomy can mimic the condition of 
accelerated bone loss in postmenopausal 
women  (8).   
The use of radionuclides for bone scan 
imaging using 99mTc-MDP is still the first 
choice for clinicians in hospitals to detect 
bone disease and its metabolism. Research 
in Indonesia was observed uptake of 99mTc-
MDP in prostate cancer patients with bone 
metastatic cases at 20 prostate cancer 
patients, and the uptake was increased in 
metastatic cases (9). Research conducted by 
Moore et al showed that there is a visual 
change from 99mTc-MDP when giving 
teriparatide drug therapy in osteoporosis 
patients (10). The mechanism of 99mTc-MDP 
accumulation is attached to areas of 
calcification or active bone metabolism 
especially the surface of hydroxyapatite from 
bones and crystalline structure of 
hydroxyapatite (11). Another mechanism was 
found that the accumulation of 99mTc-MDP 
was related to its binding with immature 
collagen (12).  
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It has been observed that 99mTc-MDP 
can be used for bone scintigraphy especially 
in case of bone cancer and some interaction 
with osteoporotic drugs in osteoporosis 
patient, but biodistribution data of 99mTc-MDP 
on ovariectomized mice for early monitoring 
of osteoporosis model remains unclear. This 
study aimed to examine the biodistribution of 
99mTc-MDP both in normal and 
ovariectomized mice to identify whether 
99mTc-MDP can be used for early detection of 
osteoporosis. 
 
2. METHODOLOGY 
Animal Models 
Eighteen female BALB/c mice with 30 g 
body weight from PT Biofarma, Tbk Bandung, 
Indonesia were housed in polypropylene 
cages (38x30 cm)  at constant temperature 
(26±1oC) and humidity (60±5%) with 12 hours 
dark cycle. The mice were given dry feed and 
water ad libitum and divided into normal 
group and ovariectomized groups. All 
protocol was approved by the Ethics 
Committee for the Care and Use of 
Laboratory Animal (KEPPHP BATAN) under 
protocol number 003/KEPPHP-
BATAN/IX/2019. 
Ovariectomy was performed using 
double dorsolateral incisions in eight week-
old mice under anesthesia. Anesthesia was 
performed using ketamine and xylazine then 
the flank area between the last rib and above 
the pelvis was shaved. The skin was 
disinfected with chlorhexidine solution and 
incision was made in the skin on the right side. 
Musculature was separated with curved tip 
scissors. The ovarian was carefully pulled 
and fat pad out of the incision. The sterile 
thread was used to make two knots to 
delimitate the area. The ovary was removed 
from both sides. Analgesia was injected to 
control pain and mice were placed on a 
heating pad until it is recovered. Maintenance 
of pain was performed by adding 1.4 mL 
acetaminophen solution to 300 mL water 
(final concentration, 0.47 mg/mL) and 
maintain ad libitum for 3 days. The animal 
was observed for any inflammatory signs that 
suggest pain (13). 
Histologic evaluation 
The femur from normal mice and 
ovariectomized mice were isolated and fixed 
with 10% formalin for 24 hours, decalcified in 
EDTA. The bone sample was embedded into 
the paraffin and then cut into 4 mm slices 
along the sagittal plane through the 
longitudinal axis. The histopathology analysis 
stained with Hematoxylin Eosin (HE) and 
examined under a light microscope with 20X 
magnification. 
Preparation of 99mTc-MDP  
The 99mTc-MDP preparation was 
conducted aseptically, natrium pertechnetate 
(Na99mTcO4) (111 MBq/3 mL) was added into 
a vial containing MDP kit from PSTNT 
BATAN. The solution was shaken and 
incubated for 30 minutes at room 
temperature, resulting in 99mTc-MDP 
radiopharmaceutical. The radiochemical 
purity of 99mTc-MDP was determined using 
two paper chromatography systems. In the 
first step, The Whatmann 3MM 
chromatography paper was used as a 
stationary phase and 100% acetone as 
mobile phase for separating reduced 99mTc 
(99mTcO2) and 99mTc-MDP from pertechnetate 
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ion (99mTcO4-). Then, used Whatmann 3MM 
chromatography paper as stationary phase 
and 0.9% NaCl as a mobile phase for 
separating 99mTcO2 from 99mTc-MDP and 
99mTcO4- (14).  
Biodistribution Studies 
The experiment was performed on 
BALB/c mice weighing approximately 30 g. 
Mice were divided into normal and 
ovariectomized groups with n=3 for every 
time point, referring to International Atomic 
Energy Agency (IAEA) technical report series 
No.466 for 99mTc radiopharmaceutical 
biodistribution (15). The 99mTc-MDP was 
injected into the tail vein (100 µl) with 1.85 
MBq radioactivity. At the time point of 1, 2, 
and 3 hours mice was euthanized using 
accepted protocol and the tissue of interest 
was collected. All tissue and blood were 
weighed using an analytical scale and 
counted for radioactivity using Automatic 
Gamma Counter with NaI(Tl) detector. The 
percentage of radioactivity per gram of tissue 
weight (%ID/g) was determined using the 
following formula : 
%ID/g =  
                   
                
x 100% 
Data Analysis 
Numerical data that conformed to a 
normal distribution were expressed as mean 
± SD. The biodistribution for a normal group 
and ovariectomized group for every time 
interval using One Way ANOVA. Data 
comparison between normal and 
ovariectomized groups were compared using 
independent t-test with significance level  
p<0.05. 
3. RESULT AND DISCUSSION  
Based on Figure 1, ovariectomy 
procedures affect the bone structure in the 
femur of BALB/c mice. Samples showed that 
quite clear the femoral head and middle of the 
diaphysis bone loss at figure 1 (B), compared 
with normal mice figure 1 (A). Estrogen 
deficiency caused by the procedure causes 
bone loss is the stimulation of osteoclast 
differentiation (16).  
Radiochemical Purity 
In vivo application of 
radiopharmaceutical has a quality 
requirement that is clarity, sterility, non-
pyrogenicity, pH, and radiochemical purity. In 
this study, radiochemical purity testing was 
performed using two ascending 
chromatography system. Figure 2A showed a 
radiochromatogram of 99mTc-MDP, where 
acetone used as a mobile phase, 99mTc-MDP 
and 99mTcO2 stayed at origin give Rf = 0 while 
99mTcO4- moved with solvent to give Rf = 1. 
Figure 2B showed the radiochromatogram 
result of 99mTc-MDP where saline solution 
used as a mobile phase. 99mTcO2 stayed at 
origin give Rf = 0 while 99mTc-MDP and 
99mTcO4- moved with the solvent to give Rf = 
1. Two ascending chromatography tests 
showed that 99mTc-MDP had 99,98% 
radiochemical purity with n=3. The result has 
been confirmed to United States of 
Pharmacopoeia that the radiochemical purity 
should be greater than 95% for in vivo 
application.  
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(A) Normal Mice 
  
(B) Osteoporosis Mice 
Figure 1. Normal mice (A) and Osteoporosis mice (B) photomicrographs showing a significant bone loss in 
the femur at the femoral head and middle of the diaphysis (hematoxylin and eosin stain; original 
magnifications, 20X) 
 
  
(A) (B) 
 
Figure 2. (A) Radiochromatogram of 99mTc-MDP using aceton as mobile phase (B) Radiochromatogram of 
99mTC-MDP using saline solution as mobile phase 
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Biodistribution Study 
Biodistribution of 99mTc-MDP both in 
normal and ovariectomized mice group was 
studied 1, 2, and 3 hours post-injection to 
evaluate the optimum time of 
radiopharmaceutical accumulation for every 
time interval.  
Data from Table 1 shows for the first 
three hours post-injection higher 
physiological uptake was observed in bone, 
liver, and kidney both in normal and 
ovariectomized mice. Data analysis 
conducted in the normal group showed a 
decrease in the radioactivity accumulation in 
each organ at different time intervals. On the 
other hand, the ovariectomy group showed 
retention of radioactive accumulation in 
kidney and liver organs related to increased 
bone resorption and reduced of bone 
formation in osteoporosis conditions, the 
exact mechanism still remains unknown (17).  
Statistical analysis using independent t-test 
proves that for normal mice physiological 
uptake was significantly different in the bone 
as target organ with p<0.05.  
 
 
Table 1. (A) Biodistribution Data of 99mTc-MDP in normal and ovariectomized mice (Ovx) expressed 
as %Injected dose/g tissue (ID/g) (mean value ± SD, n = 3).  
 
Organ 
Normal 
Sig 
(p<0.05) 
Ovx 
Sig 
(p<0.05) 
1 2 3  1 2 3  
Muscle 0.08±0.02 0.06±0.01 0.05±0.02 0.08 0.08±0.15 0.06±0.01 0.05±0.02 0.08 
Bone 20.32±1.38 13.75±0.01 12.18±1.44 0.00 7.42±2.61 5.25±0.25 4.86±1.34 0.00 
Blood 0.44±0.01 0.29±0.10 0.14±0.01 0.00 0.50±0.09 0.30±0.11 0.22±0.06 0.00 
Intestine 0.19±0.01 0.15±0.04 0.14±0.05 0.08 0.21±0.03 0.22±0.12 0.13±0.03 0.08 
Liver 4.04±0.41 3.64±0.60 2.96±0.39 0.07 2.73±0.21 3.13±0.10 4.07±0.59 0.67 
Kidney 1.56±0.39 1.20±0.21 1.02±0.20 0.11 2.35±0.11 1.45±0.39 1.68±0.59 0.11 
Hearth 0.34±0.07 0.31±0.08 0.19±0.01 0.03 0.22±0.05 0.15±0.02 0.11±0.03 0.03 
Lung 0.69±0.19 0.36±0.02 0.33±0.02 0.00 0.54±0.15 0.37±0.01 0.32±0.14 0.00 
Stomach 0.31±0.05 0.20±0.02 0.16±0.04 0.01 0.31±0.05 0.19±0.02 0.16±0.04 0.01 
 
Figure 3 shows that the administration of 
99mTc-MDP on ovariectomized mice also 
changed the physiological uptake in mice 
organs. The higher physiological uptake was 
found in bone, liver, and kidney. Based on 
statistical analysis for every time interval with 
(p<0.05), data obtained were significantly 
different. The highest uptake of 99mTc-MDP 
was found at 1 hour post-injection in bone 
(7.42±2.61) %ID/g. The liver has the highest 
physiological uptake 3 hours post-injection 
(4.07±0.59) %ID/g. The higher uptake of 
99mTc-MDP in the liver at 3 hours as shown 
on Figure 4(c) may be due to changes in liver 
function caused by osteoporosis, although 
this needs further study. Research conducted 
by Nackhbandi showed that there is a link 
between liver function and osteoporosis (18). 
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(A) 1 hours post injection (B) 2 hours post injection 
 
(C) 3 hours post injection 
 
Figure 3. Biodistribution profile of 99mTc-MDP in normal mice and ovariectomized mice at 1 hour (a), 2 hours 
(b) , and 3 hours (c) post-injection. Data are presented as percentage Injected dose per gram organ (%ID/g; 
n=3) 
 
Table 2 shows the comparison of the 
T/NT ratio of target organ (bone) with non 
target organ (muscle, liver, and kidney). The 
radioactivity accumulation shows optimum 
results based on T/NT ratio with minimum 
ratio 2:1 for application of gamma camera. 
The normal group shows T/NT ratio not 
significantly different for the first three hours. 
On the other hand ovariectomized group 
shows the ratio T/NT decreased at 2 hours 
because the 99mTc-MDP distributed in the soft 
tissue. The maximum value of T/NT in 
osteoporosis model was seen at 3 hours after 
administration of the tracer. The result similar 
according to the study of Sugiharti et al, an 
increase in 3 hours post-injection (14). For 
clinical application, it is expected that 
radiopharmaceuticals are localized 
specifically in target organs because of the 
activity of T/NT the structural details of the 
image in the target organ. Therefore, the ratio 
of target organs to non-target organs has a 
high activity ratio. 
Osteoporosis condition will appear 
immediately after the procedure where 
estrogen will be replaced by 17-β-estradiol. 
Bone damage occurs gradually in the 
proximal tibial metaphysis after 14 days, in 
the lumbar vertebral body after 60 days, and 
in the femoral neck after 30 days. The 
reduction of cortical thickness and 
enlargement of the bone marrow cavity begin 
between 90 and 120 days after ovariectomy 
(7). This study observed biodistribution of 
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99mTc-MDP for  30 days after the ovariectomy 
procedure has been performed and 
osteoporosis condition proven by histological 
findings. 
In ovariectomized mice, estrogen level 
was decreased which retards parathyroid 
induced calcium dissolution, resulting in 
imbalanced osteoblast and osteoclast 
activities and a high bone resorption rate. 
Ovariectomized also reduced BMD then the 
features and arrangements of collagen fibers 
and hydroxyapatite crystals are also 
expected to change. As in the ovariectomized 
collagen fibers are short and randomly 
distributed, rather than long and aligned, and 
hydroxyapatite crystals are loosely packed 
(19). 
A fundamental aspect of understanding 
the biodistribution of 99mTc-MDP is primarily 
cleared by renal and osseous pathway. The 
study results showed that the administration 
of 99mTc-MDP is related to the clearance 
mechanism where the radioactivity 
accumulation of kidney and liver is high. 
Therefore, the degree of osseous uptake 
depends not only on factors relating to bone 
metabolism but also on renal clearance, the 
latter being closely approximated by the 
glomerular filtration rate  (20).  
 
 
Table 2. 99mTc-MDP radiopharmaceutical accumulation ratio Target/Non-Target (T/NT) between normal and 
ovariectomized mice  
 
Target/Non- Target organ 
Accumulation Ratio Target/Non-Target (T/NT) 
1 hours 2 hours 3 hours 
Normal Ovx Normal Ovx Normal Ovx 
Bone : Muscle 240.32 61.42 242.82 38.50 233.64 89.92 
Bone : Liver 5.03 2.72 3.78 1.68 4.11 1.19 
Bone : Kidney 12.99 3.15 11.50 3.29 11.96 4.11 
 
 
When 99mTc-MDP is injected 
intravenously, its biodistribution depends on 
the blood flow and the uptake reflects the rate 
of new bone formation. This radiotracer 
accumulates in the inorganic hydroxyapatite 
crystal component of bone. It is therefore 
normal to see the uptake of the radiotracer 
throughout the entire skeleton. The 
radiotracer 99mTc-MDP undergoes urinary 
excretion and activity can be seen in the 
kidneys. The difference in accumulation that 
occurs in 99mTc-MDP is due to changes in 
hydroxyapatite crystals in osteoporotic bone. 
Bone porosity is proportional to the size of 
hydroxyapatite crystals, where an increase in 
porosity can increase the size of 
hydroxyapatite crystals. The normal bone will 
show the size of hydroxyapatite crystals that 
are smaller than osteoporosis because they 
have low porosity. Larger crystal sizes cause 
an increase in the number of total cavities so 
that the vacancy ratio also increases. The 
change in size and destruction of 
hydroxyapatite crystals by osteoclasts 
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causes 99mTc-MDP radiopharmaceuticals to 
be unable to bind to hydroxyapatite so that 
the accumulation of 99mTc-MDP on 
osteoporosis mice becomes lower than 
normal mice (21). 
 
4. CONCLUSION 
The application of 99mTc-MDP as bone 
scintigraphy has been widely used for clinical 
application. Osteoporosis condition in 
ovariectomized mice, shown that there are 
differences in biodistribution patterns in 
organs. The clinical application of 99mTc-MDP 
can be used to detect osteoporosis 
conditions earlier by looking at bone uptake 
and become a concern in the application for 
bone scintigraphy if the patient is indicated 
osteoporosis because it will affect 
visualization of the organ. Further research is 
needed to investigate interactions of some 
osteoporotic drugs with the 99mTc-MDP 
application and pharmacokinetic parameters 
in the osteoporosis model 
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